Zusammenfassung
ZIEL DER STUDIE: Erhebung der Serum-konzentrationen des Anti-Müller Hormons (AMH) bei adoleszenten und jungen erwachsenen chinesischen Patienten mit polycystischem Ovar Syndrom (PCOS) und Evaluierung seines diagnostischen Wertes im Rahmen des PCOS. DESIGN: Die Konzentration des AMHs wurde im Serum von 47 adoleszenten und jungen erwachsenen chinesischen Patienten mit PCOS und von 40 alters-gematchten Kontrollen gemessen. Das diagnostische Potential der AMH Konzentrationen wurde durch Erstellen von Receiver Operating Characteristics (ROC) Kurven geprüft. ERGEBNISSE: Die Serum AMH Konzentrationen waren bei den PCOS-Patienten höher als bei den Kontrollen (9,85 ± 4,93 ng/mL vs. 7,13 ± 3,02 ng/mL, P = 0,002) und korrelierten signifikant positiv mit dem mittleren Volumen des Ovars der PCOS Patienten (r = 0,319, P = 0,029). Die Fläche unter der ROC Kurve erreichte einen Wert von 0,664 (0,551–0,778, 95 % Konfidenz Intervall). Der beste Kompromiss zwischen Spezifität (70 %) und Sensitivität (61,7 %) wurde bei einem cut-off Wert von 8 ng/ml erhoben. SCHLUSSFOLGERUNGEN: Die Serum AMH Konzentrationen sind bei adoleszenten und jungen erwachsenen chinesischen Patienten mit PCOS erhöht. Die Messung der Serum AMH Konzentrationen bietet allerdings nur eine relativ schwache diagnostische Trennschärfe mit einer Sensitivität von 61,7 % und einer Spezifität von 70 % bei einem Grenzwert von 8 ng/ml.
Summary
PURPOSES: To explore the serum anti-mullerian hormone (AMH) level in adolescent and young adult Chinese patients with polycystic ovary syndrome (PCOS), and to evaluate its diagnostic value for PCOS. STUDY DESIGN: Serum AMH was measured in a cohort of 47 adolescent and young adult Chinese patients with PCOS and 40 age-matched controls. Its diagnostic potential was evaluated by Receiver Operating Characteristic (ROC) curves. RESULTS: The serum AMH level was higher in PCOS patients than in controls (9.85 ± 4.93 ng/mL vs. 7.13 ± 3.02 ng/mL, P = 0.002), and positively related to the mean ovarian volume in PCOS patients (r = 0.319, P = 0.029). The area under the ROC curve for AMH reached a value of 0.664 (0.551–0.778, 95% confidence interval). The best compromise between specificity (70%) and sensitivity (61.7%) was obtained with a cut-off value of 8 ng/mL. CONCLUSIONS: Serum AMH levels are elevated in adolescent and young adult Chinese patients of PCOS. Serum AMH measurement offers a relatively poor diagnostic potency with a sensitivity of 61.7% and a specificity of 70% at 8 ng/mL.
References
Zhu YG, Su YH, Zhang YW (2004) Polycystic ovary syndrome, In: Cao ZY (ed) Chinese Obstetrics and Gynecology, 2nd edn. Republic Health Publishing Company, Beijing, pp 2448–1
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41–7
Balen AH, Dunger D (2004) The polycystic ovary syndrome and adolescent women. In: Balen AH, Creighton SM, Davies MC, Macdougall J, Stanhope R (eds) Paediatric and adolescent gynaecology, 1st edn. Cambridge University Press, Cambridge, pp 342–53
Salmi DJ, Zisser HC, Jovanovic L (2004) Screening for and treatment of polycystic ovary syndrome in teenagers. Exp Biol Med (Maywood) 229: 369–77
Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, et al (1986) Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell 45: 685–98
Juengel JL, Hudson NL, Whiting L, Menatty KP (2005) The role of proteins of the transforming growth factor-beta superfamily in the intraovarian regulation of follicle development. Hum Reprod Update 11: 143–60
Munsterberg A, Lovell-Gadge R (1991) Expression of the mouse anti-mullerian hormone gene suggests a role in both male and female sexual differentiation. Development 113: 613–24
Visser JA, De Jong FH, Laven JS, Themmen APN (2006) Anti-mullerian hormone: a new marker for ovary function. Reproduction 13: 1–9
de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC (2002) Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77: 357–62
Baarends WM, Uilenbroek JT, Kramer P, Hoogerbtugge JW, van Leeuwen EC, Themmen AP, et al (1995) Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle and gonadotropin-induced follicle growth. Endocrinology 136: 4951–62
Bezard J, Vigier B, Tran D, Mauleon P, Josso N (1987) Immunocytochemical study of anti-Mullerian hormone in sheep ovarian follicles during getal and post-natal development. J Reprod Fertil 80: 509–16
Weenen C, Laven JS, von Bergh AR, Cranfield M, Groome NP, Visser JA, et al (2004) Anti-mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10: 77–83
Durlinger AL, Visser JA, Themmen AP (2002) Regulation of ovarian function: the role of anti-mullerian hormone. Reproduction 124: 601–9
Broekmans FJ, Visser JA, Laven JS, Broer SL, Themmen AP, Fauser BC (2008) Anti-mullerian hormone and ovarian dysfunction. Trends Endoicrinol Metab 19: 340–7
Wang JG, Nakhuda GS, Guarnaccia MM, Sauer MV, Lobo RA (2007) Mullerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am J Obstet Gynecol 196: 77.e1–5
Laven JS, Mulders AG, Visser JA, Themmen AP, deJong FH, Fauser BC (2004) Anti-mullerian hormone serum concentration in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89: 318–23
Pigny P, Merlen E, Robert Y, Cortet-rudelli C, Decanter C, Jonard S, et al (2003) Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88: 5957–62
Pigny P, Jonard S, Robert Y, Dewaily D (2005) Serum anti-mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 91: 941–5
Li L, Yang DZ, Chen XL, Chen YX, Feng SY, Wang LA (2007) Clinical and metabolic features of polycystic ovary syndrome. Int J Gynecol Obstet 97: 129–34
Chen XL, Yang DZ, Li L, Feng SY, Wang LA (2006) Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. Hum Reprod 21: 2027–32
Chen YX, Li L, Chen XL, Zhang QX, Wang WJ, Li Y, Yang DZ (2008) Ovarian volume and follicle number in the diagnosis of polycystic ovary syndrome in Chinese women. Ultrasound Obst Gyn 32: 700–3
Shi Y, Guo M, Yan J, Sun W, Zhang X, Geng L, et al (2007) Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuro Endocrinol Lett 28: 807–10
Zhao JL, Chen ZJ, Shi YH, Geng L, Ma ZW, Li Y, et al (2007) Investigation of body hair assessment of Chinese women in Shangdong region and its preliminary application in polycystic ovary syndrome patients. Zhonghua fu chan ke za zhi 42: 590–4 [Chinese]
Inoue S, Zimmet P, Caterson I, Chen CM, Ikeda Y, AK Khalid DD, et al (2000) The Asia-Pacific perspective: redefining obesity and its treatment. The 1st edn. Health Communications Australia Pty limited on behalf of the Steering Committee, pp 15–21
Al-Qahtani A, Muttukrishna S, Appasamy M, Johns J, Cranfield M, Visser JA, et al (2005) Development of a sensitive enzyme immunoassay for anit-mullerian hormone and the evaluation of potential clinical applications in males and females. Clin Endocrinol 63: 267–73
Chen XL, Yang DZ, Mo YQ, Li L, Chen YX, Huang YH (2008) Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gyn R B 139: 59–64
Massin N, Meduri G, Bachelot A, Misrahi M, Kuttenn F, Touraine P (2008) Evaluation of different markers of the ovarian reserve in patients presenting with premature ovarian failure. Mol Cell Endocrinol 282: 95–100
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, L., Chen, X., Mo, Y. et al. Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr 122, 519–524 (2010). https://doi.org/10.1007/s00508-010-1426-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-010-1426-x